publication date: Sep. 26, 2014


html Briefs.html

Doug Ulman Named CEO Of Fundraiser Pelotonia

DOUG ULMAN was appointed president and CEO of Pelotonia, a cycling fundraiser that has raised more than $61 million for cancer research. Ulman is president and CEO of the LIVESTRONG Foundation.

A three-time cancer survivor himself, Ulman will also work on behalf of The Ohio State University Comprehensive Cancer – James Cancer Hospital and Solove Research Institute. He also plans to be involved in the academic, business and health communities of Columbus.

The new $1.1 billion, 21-level James Cancer Hospital and Solove Research Institute will open in December 2014. Every dollar raised by Pelotonia riders will fund the research at the OSUCCC – James, according to a statement from Pelotonia.

“With cuts in federal funding for cancer research, Pelotonia has been critical to the mission of the OSUCCC – James,” said Michael Caligiuri, director of university’s cancer center.


MARGARET FOTI
, chief executive officer of the American Association for Cancer Research, received the Ellen V. Sigal Advocacy Leadership Award from Friends of Cancer Research at its Cancer Leadership Awards Reception in Washington, D.C.

During her long tenure as CEO, AACR membership has grown from 3,000 to more than 35,000 laboratory, translational, clinical, and population scientists; other health care professionals; and cancer advocates in 97 countries.

The organization opened its Washington, D.C. office in 2007 to engage with policymakers on Capitol Hill. Under Foti’s direction, the organization spearheaded a Rally for Medical Research in downtown Washington, D.C. in April 2013.


CITY OF HOPE
and Wilshire Oncology Medical Group have reached … Continue reading 40-36 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.